Educational guide
Liraglutide, A Game-Changer for Effective Weight Loss - Exploring Peptides
Liraglutide is an injectable medication approved for weight loss in adults who are obese or overweight. It is available under the name “Victoza,” and is often prescribed for weight management. Using Liraglutide may help increase feelings of fullness and reduce
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Liraglutide is an injectable medication approved for weight loss in adults who are obese or overweight. It is available under the name “Victoza,” and is often prescribed for weight management. Using Liraglutide may help increase feelings of fullness and reduce hunger, further aiding in weight loss.
What is Liraglutide?
It was approved by the FDA in 2010 for the treatment of type 2 diabetes. Later, in 2014, it was also approved for use in adults who are overweight or obese, and by 2020, it received approval for use in adolescents with similar conditions.
Mechanism of Action
Benefits of Liraglutide
Weight Loss
Glycemic Control
Increased Insulin Sensitivity
Neuroprotection
How Much Weight Can You Lose With Liraglutide?
Side Effects of Liraglutide
It’s important to note that Liraglutide has not been studied for longer than two years, so its long-term safety remains uncertain. Some of the potential, more serious issues can include:
Pancreatitis (inflammation of the pancreas)
Gallbladder problems, such as gallstones
Thyroid cancer or C-cell tumors
Kidney issues or failure
Skin rashes or lesions
Increased risk of hypoglycemia (low blood sugar), especially in type 1 diabetes patients using insulin
Irregular heartbeats or slow heart rate
Allergic reactions
The most commonly reported side effect of liraglutide is gastrointestinal discomfort. While insomnia isn’t directly related to Liraglutide, sometimes this gastrointestinal discomfort can affect sleep by making it hard to fall or stay asleep.
It’s also important to consider that liraglutide may interact with other diabetes and obesity medications. Therefore, people taking Liraglutide should consult their doctor before altering their medication regimen to ensure the safe use of all involved medications.
The Dosage
The dosage of liraglutide in research settings varies based on the study’s goals. For weight loss, the maximum recommended dosage is 3 mg/day, though this may be adjusted based on individual tolerance. To minimize side effects, researchers typically start with a lower dose and gradually increase it over five weeks
For comparison, the standard liraglutide dosage for managing type 2 diabetes is 1.2-1.8 mg/day. Research indicates that liraglutide can be used long-term at a dose of 3.0 mg/day. Most dosing protocols in studies last between 20 and 64 weeks, and the medication is generally not cycled. When the dose works well, avoid increasing it. Always target the minimum effective dose, beginning with a low amount and making adjustments slowly. We recommend that starting doses are reduced by 20 to 30% and observe how the peptide affects the body.
Is Liraglutide Safe to Use?
The FDA has approved injectable liraglutide for managing conditions such as type 2 diabetes, overweight, and obesity in individuals aged 12 and older. This approval was based on extensive data from multiple clinical trials demonstrating liraglutide’s safety and effectiveness.
Recent studies confirm that liraglutide is generally well-tolerated among most participants. Using Liraglutide for non-prescription purposes other than those approved by the FDA, such as general weight management, is not advised.
Is Liraglutide Better Than Semaglutide?
Liraglutide and Semaglutide are both injectable peptides used for managing type 2 diabetes, delivered via a prefilled pen. Liraglutide is administered daily, while Semaglutide is given once a week. Both medications are GLP-1 agonists, meaning they mimic the GLP-1 hormone to help regulate blood sugar and reduce appetite, which can support weight loss. Due to different individual responses, it’s hard to tell which one of these peptides is better, they both are effective in treating both diabetes and obesity.
Final Thoughts
Liraglutide is a GLP-1 receptor agonist approved for treating type 2 diabetes and aiding weight loss for people who are obese or overweight. Research indicates that it effectively reduces body weight and enhances glycemic control however it comes with some potential risks. Common side effects include nausea, vomiting, and diarrhea, which typically resolve over time.
Sourcing
USA
LIMITLESS LIFE NOOTROPICS aka Biotech
Use Discount Code: EP20
SCANTIFIX
Use Discount Code: Exploringpeptides
Canada
BIOSLAB
Use Discount Code: EP10
Europe
DNLABResearch
Use Discount Code: EP15
Australia
LVLUPHEALTH
References
[1] Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. PMID: 31767182; PMCID: PMC6812410.
[2] Jackson SH, Martin TS, Jones JD, Seal D, Emanuel F. Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. P T. 2010 Sep;35(9):498-529. PMID: 20975808; PMCID: PMC2957743.
[3] Xu X, Chen J, Hu L, Liang M, Wang X, Feng S, Shen J, Luan X. Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway. Life Sci. 2018 Feb 15;195:87-94. doi: 10.1016/j.lfs.2017.12.012. Epub 2017 Dec 7. PMID: 29225111.
[4] Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud. 2011 Fall;8(3):418-31. doi: 10.1900/RDS.2011.8.418. Epub 2011 Nov 10. PMID: 22262078; PMCID: PMC3280675.
[5] Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014 Jun;38(6):784-93. doi: 10.1038/ijo.2013.162. Epub 2013 Sep 3. PMID: 23999198; PMCID: PMC4052428.
[6] Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, Mohamed El-Tanani & Manfredi Rizzo. (2024) Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care. Pragmatic and Observational Research 15, pages 139-149.
[7] Ostawal A, Mocevic E, Kragh N, Xu W. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Ther. 2016 Sep;7(3):411-38. doi: 10.1007/s13300-016-0180-0. Epub 2016 Jun 27. PMID: 27350545; PMCID: PMC5014786.
[8] Zhou JY, Poudel A, Welchko R, Mekala N, Chandramani-Shivalingappa P, Rosca MG, Li L. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. Eur J Pharmacol. 2019 Oct 15;861:172594. doi: 10.1016/j.ejphar.2019.172594. Epub 2019 Aug 11. PMID: 31412267.
[9] Edison, P., Femminella, G.D., Ritchie, C.W., Holmes, C., Walker, Z., Ridha, B.H., Raza, S., Livingston, N.R., Nowell, J., Busza, G., Frangou, E., Love, S., Williams, G., Lawrence, R.M., McFarlane, B., Archer, H., Coulthard, E., Underwood, B., Koranteng, P., Karim, S., Bannister, C., Perneczky, R., Prasanna, A., Junaid, K., McGuinness, B., Nilforooshan, R., Macharouthu, A., Donaldson, A., Thacker, S., Russell, G., Malik, N., Mate, V., Knight, L., Kshemendran, S., Holscher, C., Mansouri, A., Chester-Jones, M., Holmes, J., Williams, S.C., Brooks, D.J., Harrison, J.E., Tadros, G., Passmore, A.P. and Ballard, C. (2021), Evaluation of liraglutide in the treatment of Alzheimer's disease. Alzheimer's Dement., 17: e057848. https://doi.org/10.1002/alz.057848
[10] Pi-Sunyer, Xavier, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C.W. Lau, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine, vol. 373, no. 1, 2 July 2015, pp. 11–22. DOI: 10.1056/NEJMoa1411892.
[11] Seo YG. Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes. J Obes Metab Syndr. 2021 Mar 30;30(1):12-19. doi: 10.7570/jomes20059. PMID: 33071241; PMCID: PMC8017323.
Table of content
Related articles
SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332
Adalank vs Selank: Differences, Benefits and Effects
Adamax vs Semax: Comparison, Benefits, and Effects
Common Mistakes When Reconstituting Peptides
Peptides Vs Proteins: What’s The Difference?
What Are Peptides and How Do They Work?